Problem

Mito Health addresses a preventive-care gap: health answers are often confusing, expensive, and shaped by incentives to sell more tests or treat disease after it appears. Traditional healthcare economics reward acute treatment rather than the time-consuming work of understanding sleep, nutrition, stress, family history, and early risk; a standard physical also provides far less data than a comprehensive biomarker profile. The result is that people may not know what to test, which results matter, or whether they are wasting money.

Its core use case is the prevention-minded consumer who wants to identify elevated risks or deficiencies early and take practical action without buying an indiscriminate testing package. Mito’s cost-plus model is designed to reduce the economic conflict: members pay the company’s cost to provide a test plus ordering fees, while Mito says it profits from membership rather than from selling more tests.

Product / Service

Mito is a consumer preventive-health platform combining a testing marketplace with human clinical guidance and AI-supported analysis. A user takes a short quiz and receives a personalized recommendation for what to test, what to skip, and what it will cost. Members pay $9 per month and receive laboratory testing at published cost, with clinician-reviewed next steps, longitudinal tracking, and an AI Concierge that helps assemble a panel. Testing covers more than 100 biomarkers across cardiovascular, metabolic, hormonal, inflammatory, and nutrient-related health, with services available through laboratory partners including Quest and BioReference.

The benefit is not simply a lab report but an interpretation and follow-through layer. Results are reviewed in the context of lifestyle and family history, followed by a personalized action plan and a one-to-one consultation with a health expert. For deeper assessment, Mito connects customers with BodySpec for DEXA scans and Prenuvo for preventive full-body MRI, while its concierge model provides ongoing help with booking tests, understanding results, and acting on recommendations.

Market

Mito competes in consumer preventive health and digital health, particularly against conventional primary-care screening, direct-pay laboratory testing, bundled testing subscriptions, and hospital-based labs. Its differentiation is an explicitly cost-plus marketplace and a guidance layer intended to help customers buy fewer, more relevant tests rather than maximize testing volume. The available evidence does not identify specific named direct competitors, but it does show Mito operating alongside adjacent preventive-imaging providers through partnerships with BodySpec and Prenuvo.

The company is an active, commercially operating business rather than merely pre-launch: it was accepted into Y Combinator’s Summer 2024 batch, expanded from its San Francisco launch to all 50 U.S. states, works with major lab partners, and reports serving thousands of customers. Mito reported $2.2 million in additional seed funding in March 2025, bringing total funds raised to $4 million, and reported that its customers had identified elevated risks, nutrient deficiencies, and critical conditions requiring early action. Revenue is not disclosed in the available research, so the company’s revenue scale and profitability cannot be assessed.